Your Patient Passed 20/20 — But Can They Read Their Phone?
A patient sits in your exam lane, reads the 20/20 line without hesitation, and walks out with a clean bill of visual health. Two weeks later, they're back, complaining of headaches, blurred text on their phone, and fatigue after an hour at their computer. The distance chart said everything was fine. It wasn't.
The Snellen chart was invented in 1862 to measure far-distance resolution. It was never designed to evaluate the near and intermediate visual demands that define modern life. With 1.8 billion presbyopes globally, 826 million people living with uncorrected near vision impairment, and U.S. adults averaging over 7 hours of daily screen time, the gap between what we test and what patients actually need to see has never been wider.
Distance-only acuity testing is a diagnostic blind spot, and the modern exam lane can no longer afford it.
The Snellen Chart Was Built for a Different World
When Hermann Snellen introduced his chart in 1862, the visual tasks that mattered most were recognizing faces at a distance, reading road signs, and qualifying for military service. The chart did its job well for those purposes. But its design flaws are well-documented: unequal letter spacing between lines, inconsistent size progression, and variable legibility among optotypes. The letter "E" is simply easier to identify than "B" at threshold acuity, yet both appear on the same line as if they carry equal diagnostic weight.
Contrast those 19th-century visual demands with the reality of 2026. Smartphones are held at 30 to 40 centimeters. Computer screens sit at 50 to 70 centimeters. U.S. adults spend an average of 7 hours and 2 minutes per day looking at digital screens. The tasks that matter most to patients now happen at arm's length or closer, not at 20 feet.
Despite all of this, the Snellen chart remains the dominant acuity tool in both general practice and ophthalmic offices. This is a clinical inertia problem. The ETDRS chart, widely recognized as the research gold standard, offers better design and repeatability, but its adoption in routine practice has been limited by cost, chart size, and limited availability. The result: most practitioners still rely on a 160-year-old tool to assess a visual world it was never built to measure.
What Distance-Only Testing Misses: A Clinical Breakdown
Near visual acuity governs the tasks most patients care about most: reading a book, scrolling through a phone, reviewing a medication label, cooking from a recipe. It is arguably more relevant to daily function than distance acuity for the majority of the patient population. Yet near vision testing remains routinely undertested in standard exam workflows.
The clinical consequences are specific and measurable. Distance-only testing fails to detect or adequately characterize several conditions:
- Presbyopia: The most common cause of near vision impairment worldwide, affecting 1.8 billion people, cannot be quantified without a near acuity measurement.
- Low vision: Near acuity is a better predictor of the optimal magnification needed by visually impaired readers than distance acuity alone.
- Accommodative dysfunction and convergence insufficiency: These conditions manifest at near distances and are invisible to a 20-foot chart.
- Amblyopia: Research has shown that near visual acuity is significantly better than distance visual acuity in amblyopic eyes. Distance-only testing can miss or mischaracterize the condition entirely.
Among young adult screen users aged 20 to 34, 22.5% exhibit binocular vision dysfunctions. These conditions are completely invisible to a Snellen chart but become apparent through near vision assessment. Globally, 66% of screen users experience symptoms of Computer Vision Syndrome, and 44.1% of school-age children report digital eye strain. These symptoms are driven by near and intermediate vision dysfunctions that distance charts cannot identify.
The WHO classifies near visual acuity worse than N6 or M0.8 at 40 centimeters as near visual impairment. That classification cannot be made with a distance chart. If you are not testing near acuity, you cannot diagnose near vision impairment by any recognized global standard.
Near vs. Intermediate: A Distinction That Changes the Prescription
"Near" and "intermediate" are not interchangeable terms. Near vision testing is typically conducted at 40 centimeters, while intermediate distances fall between 50 and 70 centimeters. These represent fundamentally different accommodative demands and require different testing protocols.
Smartphones are generally held at 30 to 40 centimeters, placing them in the near range. Computer screens sit at 50 to 70 centimeters, squarely in the intermediate zone. A standard 40-centimeter near chart may not reflect the primary working distance for a patient who spends most of their day at a desktop monitor.
Testing distance should be adjusted based on occupation, device use habits, and the patient's chief complaint. A graphic designer's visual demands differ substantially from a surgeon's or a student's. Clinical trials for premium IOLs already recognize this: they mandate separate distance (4 meters), intermediate (66 centimeters), and near (40 centimeters) acuity endpoints. That tripartite standard is rarely replicated in routine exams, but the clinical logic behind it applies to every patient.
The Standardization Crisis: Jaeger, N-Notation, and the Tower of Babel
Near vision notation is, to put it plainly, a mess. Jaeger numbers, N-notation, M-units, and logMAR near charts all coexist in clinical practice with no universal standard. A patient's near acuity recorded as "J2" in one office may not mean the same thing as "J2" in another, because the Jaeger system has no standardized external definition.
The International Council of Ophthalmology has stated this directly: Jaeger numbers are "extremely variable" and unsuitable for near vision testing. Yet they remain in widespread use, printed on near cards found in exam lanes around the world.
A 2025 comparative validation study published in Ophthalmology Science confirmed what many clinicians have long suspected: results from ETDRS near charts, N-notation charts, and Rosenbaum near cards are not directly interchangeable. This creates real downstream problems. Clinical records become inconsistent. Referral communication between providers loses precision. And routine exam findings cannot be meaningfully compared with clinical trial outcomes that use ETDRS-based protocols.
The gap between the clinical trial standard (ETDRS near charts at 40 centimeters with calibrated illumination) and the general practice reality (a Rosenbaum card held at an uncontrolled distance under variable lighting) is significant. Closing that gap starts with choosing validated, standardized near vision tools.
The Growing Patient Populations That Demand Near Vision Data
Presbyopia: With 1.8 billion presbyopes globally and projections reaching 2.1 billion by 2030, the demand for near vision testing is growing every year. Adults aged 50 to 59 have nearly 12 times higher odds of presbyopia compared to those aged 35 to 39. For practices serving aging populations, near vision testing is both a clinical necessity and a commercial imperative.
Post-IOL and post-refractive surgery patients: The rapid adoption of premium multifocal and extended depth-of-focus IOLs has created a patient population that expects verified performance at distance, intermediate, and near. A distance chart alone cannot confirm whether a $4,000-per-eye lens is delivering on its promise. Tripartite acuity testing is the only way to assess these outcomes properly.
Pediatric patients: Near vision testing is critical for detecting accommodative esotropia, convergence insufficiency, and reading-related vision problems in children. Yet near testing is largely absent from standard pediatric exam workflows, leaving these conditions undetected until they affect academic performance.
Screen-dependent young adults: U.S. teenagers average over 7 hours of recreational screen time daily before school-related use is factored in. Among digital device users aged 20 to 34, 22.5% show binocular vision anomalies. This population faces intense near and intermediate visual demand but is rarely given near acuity testing.
Low vision patients: For visually impaired readers, near acuity is a better predictor of optimal magnification than distance acuity. Near visual acuity measurement is essential for effective low vision rehabilitation planning, guiding the selection of magnification devices and reading aids.
Closing the Gap: What a Complete Near Vision Protocol Looks Like
A clinically complete near vision assessment includes several key components: a standardized chart (logMAR-based and ETDRS-compliant where possible), a controlled testing distance matched to the patient's habitual working distance, and consistent illumination. Each of these variables affects the result, and each should be documented.
Testing distance should be individualized, not arbitrarily fixed. A patient whose chief complaint involves computer work at 60 centimeters needs assessment at that distance, not only at the standard 40 centimeters. Occupation, device use habits, and the reason for the visit should all inform the protocol.
Good-Lite ETDRS near charts, designed for 40-centimeter testing, are specified as required equipment in multiple FDA-registered clinical trials for next-generation IOLs. That level of clinical credibility matters when you need confidence in your measurements.
Defocus curves are an emerging tool worth incorporating, particularly for presbyopic corrections. They provide granularity on how a lens performs across a continuous range of distances, supplementing the discrete measurements taken at fixed points. For post-IOL patients especially, defocus testing offers a more complete picture of functional vision.
Document near acuity using a consistent notation system across all visits. This enables meaningful longitudinal comparison and allows your findings to align with clinical trial benchmarks when needed. With 66% of screen users experiencing Computer Vision Syndrome symptoms, near vision assessment directly addresses the most common complaint driving patients into your office. It is both a diagnostic imperative and a practice-builder.
The Exam Lane Has to Catch Up
The visual demands of modern patients have outpaced the diagnostic tools most exam lanes rely on. Screens, aging populations, premium IOLs, and pediatric near tasks all require acuity data that a distance chart cannot provide. Near vision testing is not an optional add-on. It is a clinical standard supported by WHO classifications, IOL trial protocols, and a growing body of published evidence.
Take a hard look at your current near vision testing workflow. Evaluate whether your charts are standardized, whether your testing distances reflect real patient needs, and whether your notation system allows for reliable comparison over time. If the answer to any of those questions is uncertain, the tools exist to fix it.
Good-Lite has been a trusted partner to eye care professionals since 1930, providing clinically validated, trial-grade near vision testing tools for every practice setting. Your patients' visual world has changed. Your exam lane should reflect that.
